A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 8
- Registration Number
- NCT03360903
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Phase 2
Suspended
- Conditions
- Thyroid CancerSalivary Gland Cancer
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 46
- Registration Number
- NCT03360890
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Tolcapone in Obsessive Compulsive Disorder
Phase 2
Completed
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Drug: Tolcapone 200 MG
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 20
- Registration Number
- NCT03348930
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Implants on Mobile Health Unit
Completed
- Conditions
- Contraception
- Interventions
- Device: Nexplaon
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 1
- Registration Number
- NCT03347539
- Locations
- 🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
- Conditions
- Immune System DiseasesMultiple Sclerosis
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 30
- Registration Number
- NCT03344094
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Phase 1
Recruiting
- Conditions
- Chronic Myeloid LeukemiaMyelofibroses
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 18
- Registration Number
- NCT03326310
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
Phase 2
Withdrawn
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT03325465
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
Completed
- Conditions
- Contrast-induced Nephropathy
- Interventions
- Other: Exposure to CBCIN risk score
- First Posted Date
- 2017-10-10
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 5
- Registration Number
- NCT03305874
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Feasibility of At-Home Handheld Spirometry
Not Applicable
Terminated
- Conditions
- COPD
- Interventions
- Device: SpiroPD
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 8
- Registration Number
- NCT03284203
- Locations
- 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States
Tau PET Imaging in Atypical Dementias
Phase 1
Active, not recruiting
- Conditions
- Primary Progressive Aphasia With Suspected Alzheimer's Disease
- Interventions
- Drug: 18F-AV-1451Device: PET
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 70
- Registration Number
- NCT03283449
- Locations
- 🇺🇸
University of Chicago - American School Building, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath